The closing date for the CoNoR Study Workstream 3 online questionnaire survey is Friday 15th January 2021

If you are a surgeon or radiologist (consultants and trainees) who is regularly involved in multidiscplinary discussions on the resectability of colorectal liver metastases who has not yet completed this survey, please complete by clicking on the link below:

https://www.surveygizmo.com/s3/5438921/CoNoR

 

CLiFF and CoNoR Study Summaries:

 The CLiFF Study: 

Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases

The CLiFF Study is running at the Christie NHS Foundation Trust in Manchester, UK, utilising two novel technologies to assess changes in the liver related to pre-operative chemotherapy for colorectal liver metastases:

  1. Humedics LiMAx Test to assess liver function
  2. Advanced MR imaging (including the Perspectum Diagnostics LiverMultiScan) to assess changes in liver fat

Follow the CLiFF Study on Twitter for updates @CLiFF_Study

 

The CoNoR Study:

Colorectal Liver Metastases: Novel Assessment Tools for Resectability

The CoNoR Study involves an international survey of Hepatobiliary experts aiming to establish the potential added benefit of two novel technologies in assessing the resectability of colorectal liver metastases prior to surgery:

  1. Humedics LiMAx Test to assess liver function (LiMAx)
  2. Perspectum Diagnostics Advanced pre-operative MR Imaging Planning tool (HepaT1ca)

The four worksteams of the CoNoR study are:

 Follow the CoNoR Study on Twitter for updates @CoNoR_Study